U.S. Construction Stock News

NYSE:COUR
NYSE:COURConsumer Services

Coursera (COUR) Valuation Check After Mixed Long Term Returns And Undervalued Narratives

Coursera stock snapshot and recent performance Coursera (COUR) closed at US$6.41, with the share price showing a small gain over the past month but a decline over the past 3 months and past year, including a negative 3 year total return. The company reports annual revenue of US$757.5m and a net loss of US$51.0m. Recent annual figures indicate positive revenue and net income growth, factors some investors watch when assessing an education technology platform. See our latest analysis for...
NYSE:ACN
NYSE:ACNIT

Accenture Mistral AI Alliance Tests Growth Potential In Enterprise And European AI

Accenture (NYSE:ACN) has entered a multi-year partnership with French AI research firm Mistral AI to co-develop and deliver enterprise-grade AI solutions. The collaboration aims to embed Mistral AI’s models into Accenture’s internal operations and client offerings. Accenture plans to roll out dedicated training programs and regionally tailored AI solutions as part of this partnership. Accenture is moving to deepen its AI capabilities at a time when its share price, at $207.79, reflects a...
NYSE:ARLO
NYSE:ARLOElectronic

Arlo Technologies (ARLO) Earnings Turn Positive Challenging Skeptical Profitability Narratives

Arlo Technologies (ARLO) closed out FY 2025 with Q4 revenue of US$141.3 million and basic EPS of US$0.05, alongside net income of US$5.8 million. The trailing 12 month line shows revenue of US$529.3 million and basic EPS of US$0.14 as the business moves further into consistent profitability. Over the past six quarters, the company has seen revenue range from US$119.1 million to US$141.3 million per quarter, with basic EPS shifting from a loss of US$0.05 in late 2024 to positive contributions...
NasdaqCM:EXAS
NasdaqCM:EXASBiotechs

Exact Sciences Vote Clears Path To Abbott Deal And Valuation Recheck

Shareholders of Exact Sciences, ticker NasdaqCM:EXAS, have approved the company’s acquisition by Abbott Laboratories. The vote clears a key hurdle for the transaction to proceed and marks a major corporate milestone. The deal is expected to reshape Exact Sciences’ role within the broader diagnostics and medical technology space. Exact Sciences focuses on diagnostics, including cancer related testing, which sits at the intersection of healthcare services and medical technology. The...
NasdaqGS:CCC
NasdaqGS:CCCSoftware

Why CCC (CCC) Is Up 14.9% After New AI Milestone, EvolutionIQ Deal and $500 Million Buyback

In February 2026, CCC Intelligent Solutions Holdings reported fourth-quarter 2025 revenue of US$277.87 million and net income of US$8.12 million, crossing US$1.06 billion in full‑year sales and issuing 2026 revenue guidance of US$1.15 billion to US$1.16 billion. The results highlighted nearly US$100 million in annual revenue from AI solutions, the EvolutionIQ acquisition to broaden insurance end‑markets, and a new US$500 million share repurchase authorization, including an accelerated US$300...
NYSE:HLX
NYSE:HLXEnergy Services

Helix Energy Solutions Group (HLX) Valuation After Record Q4 Revenue And New Multiyear Contract Wins

Helix Energy Solutions Group (HLX) is back in focus after reporting its highest fourth quarter revenue since 2013, positive free cash flow, and year end cash and liquidity that support recently secured multiyear contracts. See our latest analysis for Helix Energy Solutions Group. Those results come after a busy period, with Helix Energy Solutions Group reporting full year 2025 earnings, recording a US$18.06 million long lived asset impairment, completing its share repurchase program, and...
NasdaqGS:ARQT
NasdaqGS:ARQTBiotechs

Arcutis Biotherapeutics (ARQT) Is Up 6.1% After Raising 2026 Revenue Outlook And Turning Profitable

In February 2026, Arcutis Biotherapeutics reported fourth-quarter 2025 revenue of US$129.5 million and full-year revenue of US$376.07 million, moved to a Q4 net profit of US$17.4 million, and raised its 2026 net product revenue guidance to US$480 million–US$495 million while filing an omnibus shelf registration for multiple securities. The results highlight how rapid uptake of ZORYVE across expanded indications, including pediatric use, is beginning to translate into improving profitability...
NYSE:CAAP
NYSE:CAAPInfrastructure

A Look At Corporación América Airports (NYSE:CAAP) Valuation After Passenger Traffic Climbs 8.8%

Corporación América Airports (CAAP) caught investor attention after its January 2026 operating update, with total passenger traffic rising 8.8% year on year. Argentina and Brazil led with record and double digit gains. See our latest analysis for Corporación América Airports. That operating update lands after a mixed few weeks for the share price, with a 1 day share price decline of 1.59% and a 7 day share price decline of 2.56%, but a stronger 90 day share price return of 12.43% and a very...
NasdaqGM:ODD
NasdaqGM:ODDPersonal Products

Is Oddity Tech (ODD) Now An Opportunity After A 70% Year To Date Share Price Fall

If you are wondering whether Oddity Tech is now a bargain or a value trap, a closer look at how its current share price lines up with its fundamentals can help frame that question. The stock has seen large price swings recently, with a 7 day return of 63.2% decline, a 30 day return of 64.8% decline, and a year to date return of 70.2% decline, while the 1 year return sits at 75.3% decline from the current last close of US$11.77. These moves have prompted renewed attention on the business, as...
NasdaqGS:LULU
NasdaqGS:LULULuxury

Chip Wilson’s Board Fight Puts Lululemon Governance And Valuation In Focus

Founder Chip Wilson has escalated his activist campaign at lululemon athletica by pushing for a board overhaul and governance reforms. Wilson is seeking to add three independent directors, declassify the board, and has publicly criticized current governance and brand oversight. The campaign has moved into a full proxy fight, bringing boardroom tensions into the open for shareholders of NasdaqGS:LULU. lululemon athletica, traded as NasdaqGS:LULU, is coming into this governance fight after a...
NYSE:SBR
NYSE:SBROil and Gas

Assessing Sabine Royalty Trust (SBR) Valuation After 2025 Income Pressure And Stronger Proved Reserve Outlook

Sabine Royalty Trust (SBR) is in focus after reporting lower royalty and distributable income for 2025, linked to weaker oil prices and production, partly offset by stronger natural gas pricing. See our latest analysis for Sabine Royalty Trust. At a share price of $72.94, Sabine Royalty Trust has recently seen a 7 day share price return of 4.36%. The 90 day share price return shows a decline of 5.76%, which contrasts with a 1 year total shareholder return of 19.65% and a very large 5 year...
NYSE:B
NYSE:BMetals and Mining

Is It Time To Reassess Barrick Mining After Strong 1‑Year Share Price Gains?

If you are wondering whether Barrick Mining is priced attractively today, you are not alone. This article focuses squarely on what the current share price might mean for value‑focused investors. The stock last closed at US$50.76, with returns of 5.8% over 7 days, a 4.2% decline over 30 days, 15.2% year to date, 192.8% over 1 year and 229.7% over 3 years, which can affect how the market currently thinks about its potential and its risks. Recent news around Barrick Mining has highlighted...
NYSE:CTRI
NYSE:CTRIConstruction

Centuri Holdings Backlog And Expansion Put Record 2025 Profits To Test

Centuri Holdings (NYSE:CTRI) reported record revenue and profitability for 2025. The company secured a 59% increase in backlog to $5.9b, supporting 2026 revenue visibility. Centuri announced expansion into new states and maintained a 100% Master Service Agreement renewal rate. Management is adjusting fleet funding and working to reduce seasonality in its gas business. Centuri Holdings enters 2026 with fresh momentum, backed by record 2025 financial results and a growing project book. The...
NYSE:WEX
NYSE:WEXDiversified Financial

Is It Time To Reassess WEX (WEX) After Its Multi‑Year Share Price Slide?

If you are wondering whether WEX at around US$149 per share is offering fair value or a potential bargain, you are not alone in questioning what the current price really reflects. Over shorter periods the stock has been under pressure, with a 5.2% decline over the past week, a 3.5% decline over 30 days, a 5.0% decline over 1 year and a 30.3% decline over 5 years, while the year-to-date return sits at 0.5%. These moves have come as investors continue to reassess payment and fintech related...
NYSE:AWK
NYSE:AWKWater Utilities

American Water Works Invests Over US$1b As Valuation Premium Persists

American Water Works Company (NYSE:AWK) and its subsidiaries have announced multi state infrastructure investment programs exceeding US$1b to upgrade water and wastewater systems. The initiatives focus on modernizing aging infrastructure, improving system reliability, and reducing service disruptions across several regions. The American Water Charitable Foundation has also launched its 2026 grant program to support water, conservation, and environmental education projects in local...
NasdaqGS:LCID
NasdaqGS:LCIDAuto

Lucid Balances 12% Job Cuts With Autonomy Push And New Models

Lucid Group (NasdaqGS:LCID) is cutting its global workforce by 12% while pushing ahead with higher vehicle production and deliveries. The company is shifting more resources toward autonomous driving capabilities and a potential robotaxi offering. Lucid is also planning new vehicle launches as part of a broader effort to address ongoing losses and improve operational efficiency. Lucid Group, known for its premium electric vehicles, is trying to balance cost control with growth as the EV...
NYSE:AMT
NYSE:AMTSpecialized REITs

A Look At American Tower (AMT) Valuation After Q4 Beat Guidance And Buybacks

American Tower (AMT) has been in focus after Q4 2025 revenue and profitability topped estimates, 2026 guidance was issued, a share repurchase was completed, and new data center partnerships were announced. See our latest analysis for American Tower. The latest results and 2026 outlook have come alongside a 1 month share price return of 7.84% and a year to date share price return of 9.52%. The 1 year total shareholder return shows a decline of 3.63%, which contrasts with a 10.85% gain over...
NasdaqGS:OS
NasdaqGS:OSSoftware

OneStream (OS) Turns First Quarterly Profit As Bulls Test Profitability Narrative

OneStream (OS) just closed out FY 2025 with Q4 revenue of US$163.7 million, Basic EPS of US$0.01, and net income of US$1.0 million, set against trailing 12 month revenue of US$601.9 million and a loss of US$50.3 million. The company has seen quarterly revenue move from US$132.5 million in Q4 FY 2024 to US$163.7 million in Q4 FY 2025, while Basic EPS shifted from a loss of US$0.10 to a slight profit of US$0.01 over the same period. This frames a story where top line growth is occurring...
NasdaqGS:MQ
NasdaqGS:MQDiversified Financial

Why Marqeta (MQ) Is Down 9.4% After Issuing 2026 Guidance With Block Contract Headwinds

In the past week, Marqeta reported Q4 2025 results showing sales of US$172.11 million, a net loss of US$1.39 million, record total processing volume above US$100 billion, and new Fortune 500 wins, while also issuing 2026 guidance for mid‑teens net revenue and gross profit growth. At the same time, Marqeta flagged that revised, lower pricing and volume shifts with its largest customer, Block, are expected to create headwinds for 2026 gross profit despite the strong recent operating...
NYSE:BLK
NYSE:BLKCapital Markets

BlackRock Weighs AES Deal To Expand Infrastructure And Energy Exposure

BlackRock's Global Infrastructure Partners and EQT are in advanced talks to acquire energy company AES. The potential deal would represent a large transaction in the global infrastructure and energy space. The discussions highlight BlackRock's focus on expanding its infrastructure exposure via NYSE:BLK. For you as an investor watching NYSE:BLK, these talks sit at the intersection of asset management and real world energy assets. BlackRock already runs one of the largest infrastructure...
NasdaqGS:MELI
NasdaqGS:MELIMultiline Retail

Why MercadoLibre (MELI) Is Down 12.0% After Q4 Margin Squeeze Amid Surging Revenue Growth

In late February 2026, MercadoLibre reported fourth-quarter 2025 revenue of about US$8.76 billion, up from roughly US$6.06 billion a year earlier, while quarterly net income slipped to about US$559 million from roughly US$639 million as heavier spending compressed margins. For 2025 as a whole, revenue climbed to about US$28.89 billion and net income edged up to roughly US$1.997 billion, as Mercado Pago’s rapid payment and credit expansion and higher logistics and AI investment increasingly...
NasdaqGS:BBIO
NasdaqGS:BBIOBiotechs

BridgeBio Pharma Sees Pivotal Shift As Late Stage Success Meets Attruby Sales

BridgeBio Pharma (NasdaqGS:BBIO) released positive top line Phase 3 data for Encaleret, BBP-418 and Infigratinib. The company reported strong commercial momentum for its product Attruby, supporting a move toward cash generation. Management framed this combination of clinical and commercial news as a pivotal inflection in the business model. BridgeBio Pharma comes into this update with a current share price of $66.445 and a very large 3 year return, alongside a 90.4% return over the past...
NYSE:FOR
NYSE:FORReal Estate

Is It Time To Reassess Forestar Group (FOR) After Its Strong Multi Year Share Price Run

If you are wondering whether Forestar Group's current share price reflects its true worth, you are not alone. This article is built to help you connect the recent share moves with what the fundamentals may be saying about value. Forestar Group's stock last closed at US$28.72, with returns of 4.0% decline over 7 days, 14.1% over 30 days, 18.1% year to date, 30.2% over 1 year, 98.2% over 3 years and 32.0% over 5 years. These returns sit against a backdrop of ongoing interest in US real estate...
NasdaqGS:FTRE
NasdaqGS:FTRELife Sciences

Fortrea Executive Shuffle Seeks Stronger Clinical Focus And Turnaround Potential

Fortrea Holdings (NasdaqGS:FTRE) has reshaped its executive ranks, naming Scott Dove, PhD, as President of Clinical Pharmacology Services. Oren Cohen, MD, is shifting into a more focused position as Chief Medical Officer, concentrating on Fortrea's medical direction. These changes highlight management's attention on clinical research and development within the broader contract research space. For investors watching Fortrea at a share price of $10.71, the company is pairing leadership moves...